ID   TE-9
AC   CVCL_1767
SY   TE9; Te9
DR   CLO; CLO_0051379
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1036
DR   BioSample; SAMN03472053
DR   BioSample; SAMN10987930
DR   cancercelllines; CVCL_1767
DR   Cell_Model_Passport; SIDM00325
DR   CGH-DB; 312-1
DR   CGH-DB; 9261-4
DR   ChEMBL-Cells; CHEMBL3308181
DR   ChEMBL-Targets; CHEMBL2366147
DR   Cosmic; 730340
DR   Cosmic; 735788
DR   Cosmic; 923178
DR   Cosmic; 926105
DR   Cosmic; 946353
DR   Cosmic; 983721
DR   Cosmic; 1043231
DR   Cosmic; 1123326
DR   Cosmic; 2698424
DR   Cosmic-CLP; 946353
DR   DepMap; ACH-000694
DR   EGA; EGAS00001000978
DR   GDSC; 946353
DR   GEO; GSM887702
DR   GEO; GSM888795
DR   GEO; GSM1670538
DR   LiGeA; CCLE_624
DR   LINCS_LDP; LCL-1572
DR   PharmacoDB; TE9_1585_2019
DR   PRIDE; PXD002486
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1767
DR   PubChem_Cell_line; CVCL_1767
DR   RCB; RCB1988
DR   TKG; TKG 0260
DR   TKG; TKG 0572
DR   Wikidata; Q54972023
RX   PubMed=8509434;
RX   PubMed=9023415;
RX   PubMed=9096669;
RX   PubMed=9178645;
RX   PubMed=9290701;
RX   PubMed=11115554;
RX   PubMed=15172977;
RX   PubMed=17804709;
RX   PubMed=20164919;
RX   PubMed=20515944;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 25 hours (PubMed=25984343).
CC   HLA typing: A*33:02; B*15:03 (PubMed=9023415).
CC   HLA typing: A*24:02,24:02; B*15:07,40:06; C*03:03,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.49%; East Asian, North=84.82%; East Asian, South=14.68%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: TKG; TKG 0572; probable.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 11,12
ST   D5S818: 9,13
ST   D7S820: 8,10
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   PubMed=8509434; DOI=10.1007/BF01215923;
RA   Nishihira T., Hashimoto Y., Katayama M., Mori S., Kuroki T.;
RT   "Molecular and cellular features of esophageal cancer cells.";
RL   J. Cancer Res. Clin. Oncol. 119:441-449(1993).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9096669; DOI=10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4;
RA   Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R.,
RA   Hainaut P.;
RT   "Inactivation of the p53 protein in cell lines derived from human
RT   esophageal cancers.";
RL   Int. J. Cancer 71:79-87(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11115554; DOI=10.3892/ijo.18.1.157;
RA   Fujii T., Kato S., Yamana H., Tanaka Y., Fujita H., Shirouzu K.,
RA   Morimatsu M.;
RT   "Expression of G1 cell cycle markers and the effect of
RT   adenovirus-mediated overexpression of p21Waf-1 in squamous cell
RT   carcinoma of the esophagus.";
RL   Int. J. Oncol. 18:157-163(2001).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=17804709; DOI=10.1158/0008-5472.CAN-07-2064;
RA   Boonstra J.J., van der Velden A.W., Beerens E.C.W., van Marion R.,
RA   Morita-Fujimura Y., Matsui Y., Nishihira T., Tselepis C., Hainaut P.,
RA   Lowe A.W., Beverloo H.B., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Mistaken identity of widely used esophageal adenocarcinoma cell line
RT   TE-7.";
RL   Cancer Res. 67:7996-8001(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20515944; DOI=10.1158/1535-7163.MCT-09-0918;
RA   Seki N., Toh U., Sayers T.J., Fujii T., Miyagi M., Akagi Y.,
RA   Kusukawa J., Kage M., Shirouzu K., Yamana H.;
RT   "Bortezomib sensitizes human esophageal squamous cell carcinoma cells
RT   to TRAIL-mediated apoptosis via activation of both extrinsic and
RT   intrinsic apoptosis pathways.";
RL   Mol. Cancer Ther. 9:1842-1851(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//